David Irwin

11.4k citations

66 papers · 4.2k indexed · 1 hit paper · h-index 28

Hematology top 0.2%
- Multiple Myeloma Research and Treatments 42
Oncology top 1%
- Cancer Treatment and Pharmacology 19
- Peptidase Inhibition and Analysis 5
Internal Medicine top 2%
Molecular Biology top 2%
- Protein Degradation and Inhibitors 30
- Ubiquitin and proteasome pathways 11
Emergency Medical Services top 1%
Genetics
- Chronic Lymphocytic Leukemia Research 6
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4
Infectious Diseases
- HIV/AIDS drug development and treatment 6

Co-authors: Sundar Jagannath Paul G. Richardson Kenneth C. Anderson James R. Berenson Bart Barlogie David P. Schenkein Melissa Alsina Steven Limentani
Cited by: Hematology Oncology Internal Medicine
Journals: Blood (20 papers)Journal of Clinical Oncology (12 papers)British Journal of Haematology (9 papers)
Partner nations: United States Netherlands France

In The Last Decade

David Irwin

64 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by David Irwin

Since Specialization

Citations

This map shows the geographic impact of David Irwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Irwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Irwin more than expected).

Fields of papers citing papers by David Irwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Irwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Irwin. The network helps show where David Irwin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Irwin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Irwin Line = papers co-authored together David Irwin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Black Patients with Colorectal Cancer Have More Advanced Cancer Stage at Time of Diagnosis: A Community-Based Safety-Net Hospital Experience Journal of Community Health ·Gatis Pļavenieks,Fernando Tettamanti,A PIERACH,Taft Bhuket,Benny Liu,Conrad L. Wall,David Irwin,Robert J. Wong	2016	15
2	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma British Journal of Haematology ·Dan T. Vogl,Edward A. Stadtmauer,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Thierry Façon,Jean‐Luc Harousseau,Anthony Boral,Rachel Neuwirth,Kenneth C. Anderson	2009	25
3	Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. Blood ·Paul G. Richardson,Jeffrey L. Wolf,Andrzej Jakubowiak,Jeffrey A. Zonder,Sagar Lonial,David Irwin,Amrita Krishnan,John Densmore,Noopur Raje,Michael Bär,Robert Schlossman,Irene M. Ghobrial,Nikhil C. Munshi,Thomas Martin,Jacob P. Laubach,B.K. Makhmudovich,Teru Hideshima,Lesa Gardner,Peter Sportelli,Kenneth C. Anderson	2009	11
4	Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma British Journal of Haematology ·Sundar Jagannath,Brian G.M. Durie,Jeffrey L. Wolf,Elber S. Camacho,David Irwin,Jose Lutzky,Marti McKinley,Olesya A. Muradyan,Afshin Eli Gabayan,Amitabha Mazumder,John Crowley,Robert Vescio	2009	37
5	Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma British Journal of Haematology ·William Bensinger,Sundar Jagannath,Robert Vescio,Elber S. Camacho,Jeffrey L. Wolf,David Irwin,Abdurrahman Ece,Marti McKinley,Olesya A. Muradyan,David H. Vesole,Amitabha Mazumder,John Crowley,Amadi Aroh,Mary Gilligan,Brian G.M. Durie	2009	19
6	Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study Leukemia ·Jesús F. San Miguel,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,E. Stadtmauer,Thierry Façon,JL Harousseau,Dina Ben‐Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna Reece,Joan Bladé,Mario Boccadoro,James D. Cavenagh,Rachel Neuwirth,Anthony Boral,Samuel Elias Sokolsky-Tifft,KS Anderson	2008	130
7	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma British Journal of Haematology ·Rubén Niesvizky,Paul G. Richardson,S. Vincent Rajkumar,Morton Coleman,Laura Rosiñol,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Façon,Jean‐Luc Harousseau,Anthony Boral,Dixie‐Lee Esseltine,Kenneth C. Anderson,Joan Bladé	2008	73
8	Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma British Journal of Haematology ·Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,David Irwin,Paul G. Richardson,Rubén Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Dixie‐Lee Esseltine,Kenneth C. Anderson	2008	75
9	Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma British Journal of Haematology ·Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Façon,Jean‐Luc Harousseau,Dina Ben‐Yehuda,Sagar Lonial,Jesús F. San Miguel,Jamie Cavenagh,Kenneth C. Anderson	2007	99
10	Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma: Cancer ·Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,David Irwin,S. Vincent Rajkumar,Gordan Srkalović,Melissa Alsina,Kenneth C. Anderson	2006	115
11	A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer International Journal of Radiation OncologyBiologyPhysics ·Pramila R. Anné,Mitchell Machtay,David I. Rosenthal,David M. Brizel,William H. Morrison,David Irwin,Prakash Chougule,M. Abdou,Anthony M. Berson,Walter J. Curran	2006	43
12	Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer Lung Cancer ·Paul S. Ritch,Charles M. Rudin,Jacob D. Bitran,Martin J. Edelman,P. Bonofiglio,David Irwin,Rogério Lilenbaum,Patrick Peterson,William J. John	2006	27
13	Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study International Journal of Gynecological Cancer ·Anderley Gordon,N. Finkler,Robert P. Edwards,Agustin A. García,Mark Crozier,David Irwin,Emma Barrett	2005	179
14	Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Annals of Oncology ·Meinolf Karthaus,Albrecht Kretzschmar,H. Kröning,M. Biakhov,David Irwin,Norbert Marschner,C. Slabber,George Fountzilas,A. Garin,満博伊藤,Thiadens Aa,G. Steger,T Südhoff,C. Giorgetti,Peter Reichardt	2005	159
15	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer Lung Cancer ·Tony Reid,Frank H. Valone,亜希子山田,David Irwin,Muhammd Sholikhun,吴韦 WU Wei,Sunil Sreedharan,Harold Keer,Bert L. Lum,Frank A. Scappaticci,Anish Bhatnagar	2004	138
16	Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial Leukemia ·Sima Jeha,H. Kantarjian,David Irwin,Violet Shen,S. Shenoy,Susan M. Blaney,Bruce M. Camitta,C‐H Pui	2004	118
17	Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* Breast Cancer Research and Treatment ·Edith A. Perez,Charles L. Vogel,David Irwin,Jeffrey J. Kirshner,Ravi Patel	2002	31
18	Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial Leukemia ·C‐H Pui,Sima Jeha,David Irwin,Bruce M. Camitta	2001	107
19	Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial Journal of Vascular and Interventional Radiology ·Donald Ponec,David Irwin,William D. Haire,Patricia A. Hill,Xin Li,Edward R. McCluskey	2001	107
20	High-dose chemotherapy (CTM) for breast cancer Bone Marrow Transplantation ·LE Damon,K. A. Gridnev,HS Rugo,M Negishi,AR Zander,Michael R. Cassidy,G Cecchi,因心,David Irwin,Michaël Tracy,CA Ries,CA Linker	2000	12

About David Irwin

David Irwin is a scholar working on Hematology, Oncology, Genetics, Internal Medicine and Molecular Biology, having authored 66 papers that have together received 4.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (30 papers), Cancer Treatment and Pharmacology (19 papers), Ubiquitin and proteasome pathways (11 papers), Chronic Lymphocytic Leukemia Research (6 papers), HIV/AIDS drug development and treatment (6 papers), Peptidase Inhibition and Analysis (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). The work is most often cited by research in Hematology (2.5k citations), Oncology (2.2k citations), Internal Medicine (185 citations), Molecular Biology (2.5k citations) and Emergency Medical Services (211 citations). David Irwin has collaborated with scholars based in United States, Netherlands and France. Frequent co-authors include Sundar Jagannath, Paul G. Richardson, Kenneth C. Anderson, James R. Berenson, Bart Barlogie, David P. Schenkein, Melissa Alsina, Steven Limentani, Raymond Alexanian and David S. Siegel. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Leukemia and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact